Shopping Cart 0
Cart Subtotal
USD 0

Global Nanomedicine Market - Drivers, Opportunities, Trends, and Forecasts: 2017-2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 2750

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 3000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Overview: Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 1-1,000 nm range, biochips, and polymer therapeutics.

The majority of nanomedicines used now allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and blood-brain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Market Analysis: The Global Nanomedicine Market is estimated to witness a CAGR of 17.1% during the forecast period 2017-2023. The nanomedicine market is analyzed based on two segments-therapeutic applications and regions.

Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis: Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Players: Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis: At present, the nanomedicine market is at a nascent stage-but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits: The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

READ MORE

Table Of Content

Scope

1 Industry Outlook 10

1.1 Industry Overview 10

1.2 Industry Trends 11

1.3 PEST Analysis 12

2 Report Outline 12

2.1 Report Scope 12

2.2 Report Summary 13

2.3 Research Methodology 14

2.4 Report Assumptions 14

3 Market Snapshot 16

3.1 Total Addressable Market (TAM) 16

3.2 Segmented Addressable Market (SAM) 16

3.3 Related Markets 17

3.3.1 mHealth Market 17

3.3.2 Healthcare Analytics Market 18

4 Market Outlook 18

4.1 Overview 18

4.2 Regulatory Bodies and Standards 19

4.3 Government Spending and Initiatives 19

4.4 Porter 5 (Five) Forces 21

5 Market Characteristics 22

5.1 Evolution 22

5.2 Ecosystem 25

5.2.1 Regulatory Process 25

5.2.2 Clinical Trials 25

5.2.3 Pricing and Reimbursement 26

5.3 Market Segmentation 28

5.4 Market Dynamics 28

5.4.1 Drivers 29

5.4.1.1 Emergence of nanorobotics 29

5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments 29

5.4.1.3 Reasonable investments in R&D 30

5.4.1.4 Increased support from governments 30

5.4.2 Restraints 31

5.4.2.1 Long approval process and stringent regulations 31

5.4.2.2 Problems regarding nanoscale manufacturing 31

5.4.2.3 Risks related to nanomedicines 31

5.4.2.4 Undefined regulatory standards 31

5.4.3 Opportunities 32

5.4.3.1 Aging population with chronic care needs 32

5.4.3.2 Population and income growth in emerging countries 32

5.4.4 DRO-Impact Analysis 33

6 Trends, Roadmap and Projects 34

6.1 Market Trends and Impact 34

6.2 Technology Roadmap 35

7 Types: Market Size and Analysis 36

7.1 Overview 36

7.2 Global Nanomedicine Market in Oncology Segment 37

7.3 Global Nanomedicine Market in Cardiovascular Segment 38

7.4 Global Nanomedicine Market in Neurology Segment 39

7.5 Global Nanomedicine Market in Anti-inflammatory Segment 39

7.6 Global Nanomedicine Market in Anti-infective Segment 40

7.7 Global Nanomedicine Market in Other Therapeutic Areas 41

8 Trending Nanomedicines 42

8.1 Overview 42

8.2 Abraxane 43

8.3 Alimta 43

8.4 Eligard 44

8.5 Copaxone 44

8.6 Rapamune 44

8.7 Neulasta 45

8.8 Cimzia 45

8.9 AmBisome 46

8.10 Mircera 46

8.11 Pegasys 46

8.12 Emend 47

8.13 Renagel 47

8.14 Ritalin 47

9 Regions: Market Size and Analysis 48

9.1 Overview 48

9.1.1 Global Nanomedicine Market by Geographical Segmentation 49

9.2 Key Leading Countries 49

9.2.1 US 49

9.2.2 Germany 50

9.2.3 Japan 50

10 Vendor Scenario 50

11 Vendor Profiles 53

11.1 Merck & Co. Inc. 53

11.1.1 Overview 53

11.1.2 Business Unit 55

11.1.3 Geographic Revenue 57

11.1.4 Recent Developments 58

11.1.5 SWOT Analysis 58

11.1.6 Business Strategies 60

11.2 Hoffmann-La Roche Ltd. 60

11.2.1 Overview 60

11.2.2 Business Unit 61

11.2.3 Geographic Revenue 63

11.2.4 Recent Developments 63

11.2.5 SWOT Analysis 65

11.2.6 Business Strategies 66

11.3 Gilead Sciences 66

11.3.1 Overview 66

11.3.2 Business Unit 68

11.3.3 Geographic Revenue 70

11.3.4 Recent Developments 70

11.3.5 SWOT Analysis 71

11.3.6 Business strategies 71

11.4 Novartis AG 71

11.4.1 Overview 71

11.4.2 Business Unit 72

11.4.3 Geographic Revenue 74

11.4.4 Recent Developments 74

11.4.5 SWOT Analysis 76

11.4.6 Business Strategies 76

11.5 Amgen Inc. 77

11.5.1 Overview 77

11.5.2 Business Unit 78

11.5.3 Geographic Revenue 79

11.5.4 Recent Developments 79

11.5.5 SWOT Analysis 80

11.5.6 Business Strategies 81

12 Global Generalist 82

12.1 Pfizer Inc. 82

12.1.1 Overview 82

12.1.2 Recent Developments 82

12.1.3 Pfizer in 2015 83

12.2 Eli Lilly and Company 84

12.2.1 Overview 84

12.2.2 Recent Developments 85

12.2.3 Eli Lilly and Company in 2015 85

12.3 Sanofi 86

12.3.1 Overview 86

12.3.2 Recent Developments 86

12.3.3 Sanofi in 2015 87

13 Companies to Watch for 87

13.1 Nanobiotix SA 87

13.1.1 Overview 87

13.1.2 Offering 88

13.1.3 Recent Developments 88

13.2 UCB SA 89

13.2.1 Overview 89

13.2.2 Offering 89

13.2.3 Recent Developments 90

14 Market Landscape 91

14.1 Market Landscape 91

14.1.1 Mergers & Acquisitions (M&A) 91

Annexure 93

Abbreviations 93


List Of Figure

CHART 1 PEST ANALYSIS OF NANOMEDICINE MARKET 12

CHART 2 RESEARCH METHODOLOGY OF GLOBAL NANOMEDICINE MARKET 14

CHART 3 GLOBAL NANOMEDICINE MARKET REVENUE, 2016-2023 (USD BILLION) 16

CHART 4 SHARE OF ENROLLMENT BY VARIOUS INSURANCE PROGRAMS 18

CHART 5 PORTERS 5 FORCES ON IOT HEALTHCARE MARKET 19

CHART 6 EVOLUTION OF NANOMEDICINES 20

CHART 7 ECOSYSTEM OF IOT HEALTHCARE MARKET 23

CHART 8 IOT HEALTHCARE MARKET SEGMENTATION 24

CHART 9 MARKET DYNAMICS-DRIVERS, RESTRAINTS & OPPORTUNITIES 25

CHART 10 DRO-IMPACT ANALYSIS OF IOT HEALTHCARE MARKET 29

CHART 11 TECHNOLOGY ROADMAP FOR IOT HEALTHCARE MARKET 31

CHART 12 NANOMEDICINE MARKET BY THERAPEUTIC APPLICATIONS 32

CHART 13 GLOBAL NANOMEDICINE MARKET SHARE BY THERAPEUTIC APPLICATIONS 2016 32

CHART 14 GLOBAL NANOMEDICINE MARKET REVENUE IN ONCOLOGY SEGMENT, 2016-2023 (USD BILLION) 33

CHART 15 GLOBAL NANOMEDICINE MARKET REVENUE IN CARDIOVASCULAR SEGMENT, 2016-2023 (USD BILLION) 34

CHART 16 GLOBAL NANOMEDICINE MARKET REVENUE IN NEUROLOGY SEGMENT, 2016-2023 (USD BILLION) 34

CHART 17 GLOBAL NANOMEDICINE MARKET REVENUE IN ANTI-INFLAMMATORY SEGMENT, 2016-2023 (USD BILLION) 35

CHART 18 GLOBAL NANOMEDICINE MARKET REVENUE IN ANTI-INFECTIVE SEGMENT, 2016-2023 (USD BILLION) 35

CHART 19 GLOBAL NANOMEDICINE MARKET REVENUE IN OTHER THERAPEUTIC SEGMENTS, 2016-2023 (USD BILLION) 36

CHART 20 IOT HEALTHCARE MARKET REVENUE BY TECHNOLOGIES, 2016-2022 38

CHART 21 SHORT RANGE NETWORK MARKET REVENUE, 2015-2022 (USD BILLION) 40

CHART 22 GEOGRAPHIC REVENUE IN 2016 (%) 46

CHART 23 MERCK & CO. INC.: OVERVIEW SNAPSHOT 51

CHART 24 MERCK & CO. INC.: BUSINESS UNITS 52

CHART 25 GE: GEOGRAPHIC REVENUE 53

CHART 26 MERCK & CO. INC.: SWOT ANALYSIS 55

CHART 27 HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 57

CHART 28 HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 58

CHART 29 HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE 59

CHART 30 HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 61

CHART 31 GILEAD SCIENCES: OVERVIEW SNAPSHOT 63

CHART 32 GILEAD SCIENCES: BUSINESS UNITS 64

CHART 33 GILEAD SCIENCES: GEOGRAPHIC REVENUE 66

CHART 34 GILEAD SCIENCES: SWOT ANALYSIS 67

CHART 35 NOVARTIS AG: OVERVIEW SNAPSHOT 68

CHART 36 NOVARTIS AG: BUSINESS UNITS 68

CHART 37 NOVARTIS AG: GEOGRAPHIC REVENUE 70

CHART 38 NOVARTIS AG: SWOT ANALYSIS 72

CHART 39 AMGEN INC.: OVERVIEW SNAPSHOT 73

CHART 40 AMGEN INC.: BUSINESS UNITS 73

CHART 41 AMGEN INC.: GEOGRAPHIC REVENUE 75

CHART 42 AMGEN INC.: SWOT ANALYSIS 76


List Of Table

TABLE 1 GLOBAL NANOMEDICINE MARKET REVENUE BY APPLICATION TYPE, 2017-2023 (USD BILLION) 32

TABLE 2 IOE HEALTHCARE MARKET REVENUE BY TYPE, 2016-2022 (USD BILLION) 36

TABLE 3 TECHNOLOGIES MARKET REVENUE BY TYPE, 2016-2022 (USD BILLION) 37

TABLE 4 NETWORK TECHNOLOGIES MARKET REVENUE BY RANGE, 2016-2022 (USD BILLION) 38

TABLE 5 SHORT RANGE NETWORK TECHNOLOGIES MARKET REVENUE, 2016-2022 (USD BILLION) 38

TABLE 6 IOT HEALTHCARE MARKET REVENUE BY SERVICES, 2016-2022 (USD BILLION) 42

TABLE 7 TELEMEDICINE MARKET REVENUE BY TYPE, 2016-2022 (USD BILLION) 43

TABLE 8 MERCK & CO. INC.: RECENT DEVELOPMENTS 53

TABLE 9 HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 58

TABLE 10 GILEAD SCIENCES: KEY MEDICINES/PRODUCTS 62

TABLE 11 GILEAD SCIENCES: PIPELINE PRODUCTS 63

TABLE 12 GILEAD SCIENCES: RECENT DEVELOPMENTS 65

TABLE 13 NOVARTIS AG: RECENT DEVELOPMENTS 69

TABLE 14 AMGEN INC.: RECENT DEVELOPMENTS 74

TABLE 15 PFIZER INC.: RECENT DEVELOPMENTS 77

TABLE 16 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS 79

TABLE 17 MERGER & ACQUISITION, 2014-2015 85

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Merck & Co.Inc,Hoffmann-La Roche Ltd,Gilead Sciences,Novartis AG,Amgen Inc,Pfizer Inc,Eli Lilly and Company,

Sanofi,Nanobiotix SA,UCB SA.